-
EP4330436
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4330436
| EP4330436 - THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS FOR CANCER [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 12.09.2025 Database last updated on 28.03.2026 | |
| Former | Request for examination was made Status updated on 02.02.2024 | ||
| Former | The international publication has been made Status updated on 04.11.2022 | ||
| Former | unknown Status updated on 30.05.2022 | Most recent event Tooltip | 18.03.2026 | New entry: Renewal fee paid | Applicant(s) | For all designated states GENENTECH, INC. 1 DNA Way South San Francisco, CA 94080 / US | For all designated states Icahn School of Medicine at Mount Sinai One Gustave L. Levy Place Box 1675 New York, NY 10029 / US | [2024/10] | Inventor(s) | 01 /
HAMMER, Christian South San Francisco, CA 94080-4990 / US | 02 /
HOROWITZ, Amir New York, NY 10029 / US | [2024/10] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2024/10] | Application number, filing date | 22724554.5 | 29.04.2022 | [2024/10] | WO2022US26919 | Priority number, date | US202163182307P | 30.04.2021 Original published format: US 202163182307 P | US202163226634P | 28.07.2021 Original published format: US 202163226634 P | US202163256873P | 18.10.2021 Original published format: US 202163256873 P | [2024/10] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022232503 | Date: | 03.11.2022 | Language: | EN | [2022/44] | Type: | A1 Application with search report | No.: | EP4330436 | Date: | 06.03.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.11.2022 takes the place of the publication of the European patent application. | [2024/10] | Search report(s) | International search report - published on: | EP | 03.11.2022 | Classification | IPC: | C12Q1/6886 | [2024/10] | CPC: |
C12Q1/6886 (EP,US);
A61K31/282 (US);
A61K31/337 (US);
A61K39/3955 (US);
A61P35/00 (US);
C07K16/22 (US);
C07K16/2818 (US);
C07K16/2827 (US);
A61K2039/505 (US);
A61K2039/54 (US);
A61K2039/545 (US);
C07K2317/21 (US);
C07K2317/24 (US);
C07K2317/56 (US);
C12Q2600/106 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/10] | Title | German: | THERAPEUTISCHE UND DIAGNOSTISCHE VERFAHREN UND ZUSAMMENSETZUNGEN GEGEN KREBS | [2024/10] | English: | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS FOR CANCER | [2024/10] | French: | MÉTHODES THÉRAPEUTIQUES ET DIAGNOSTIQUES ET COMPOSITIONS CONTRE LE CANCER | [2024/10] | Entry into regional phase | 08.11.2023 | National basic fee paid | 08.11.2023 | Designation fee(s) paid | 08.11.2023 | Examination fee paid | Examination procedure | 08.11.2023 | Examination requested [2024/10] | 08.11.2023 | Date on which the examining division has become responsible | 28.06.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 23.08.2024 | Amendment by applicant (claims and/or description) | 16.09.2025 | Despatch of a communication from the examining division (Time limit: M04) | 16.01.2026 | Reply to a communication from the examining division | Request for further processing for: | 23.08.2024 | Request for further processing filed | 23.08.2024 | Full payment received (date of receipt of payment) Request granted | 27.08.2024 | Decision despatched | Fees paid | Renewal fee | 15.03.2024 | Renewal fee patent year 03 | 23.04.2025 | Renewal fee patent year 04 | 17.03.2026 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY] WO2020102674 (PERSONAL GENOME DIAGNOSTICS INC et al.) | [XY] WO2020198717 (UNIV JOHNS HOPKINS et al.) | [XY] DIEGO CHOWELL ET AL: "Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy", SCIENCE, vol. 359, no. 6375, 2 February 2018 (2018-02-02), US, pages 582 - 587, XP055472400, ISSN: 0036-8075, DOI: 10.1126/science.aao4572 DOI: http://dx.doi.org/10.1126/science.aao4572 | [XY] HURKMANS DAAN P ET AL: "Tumor mutational load, CD8T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients", CANCER IMMUNOLOGY IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 69, no. 5, 12 February 2020 (2020-02-12), pages 771 - 777, XP037108912, ISSN: 0340-7004, [retrieved on 20200212], DOI: 10.1007/S00262-020-02506-X DOI: http://dx.doi.org/10.1007/s00262-020-02506-x | [XY] SHIM J.H. ET AL: "HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients", ANNALS OF ONCOLOGY, vol. 31, no. 7, 1 July 2020 (2020-07-01), NL, pages 902 - 911, XP055809044, ISSN: 0923-7534, Retrieved from the Internet DOI: http://dx.doi.org/10.1016/j.annonc.2020.04.004 | [Y] JHUNJHUNWALA SUCHIT ET AL: "Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion", NATURE REVIEWS CANCER, NATURE PUB. GROUP, LONDON, vol. 21, no. 5, 9 March 2021 (2021-03-09), pages 298 - 312, XP037439302, ISSN: 1474-175X, [retrieved on 20210309], DOI: 10.1038/S41568-021-00339-Z DOI: http://dx.doi.org/10.1038/s41568-021-00339-z | [Y] ROSENTHAL RACHEL ET AL: "Neoantigen-directed immune escape in lung cancer evolution", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 567, no. 7749, 20 March 2019 (2019-03-20), pages 479 - 485, XP036761638, ISSN: 0028-0836, [retrieved on 20190320], DOI: 10.1038/S41586-019-1032-7 DOI: http://dx.doi.org/10.1038/s41586-019-1032-7 | by applicant | US5804396 | WO2005012359 | WO8906692 | US5500362 | WO9527062 | US6884879 | US7060269 | US6582959 | US6703020 | US6054297 | WO9845332 | WO9630046 | WO9410202 | EP0666868 | US2006009360 | US2005186208 | US2003206899 | US2003190317 | US2003203409 | US2005112126 | WO2019198051 | US7129330 | US9035026 | WO0111059 | US2018030138 | US2018037655 | WO2015033301 | WO2015033299 | WO2010077634 | US8217149 | WO2011066389 | US2013034559 | WO2007005874 | US2016108123 | WO2016000619 | WO2012145493 | US9205148 | WO2013181634 | WO2016061142 | WO2010027827 | WO2011066342 | WO2012168944 | WO2015036927 | WO2015044900 | WO2015033303 | WO2013144704 | WO2013132317 | WO2011161699 | WO2006121168 | WO2009114335 | WO2015112800 | WO2015112805 | WO2015112900 | US2015210769 | WO2016089873 | WO2015035606 | WO2015085847 | WO2014206107 | WO2015119930 | WO2015119923 | WO2016032927 | WO2014179664 | WO2016106160 | WO2014194302 | WO2017114497 | WO2017117112 | ZEHIR ET AL., NAT. MED., vol. 23, 2017, pages 703 - 713 | "UniProt", Database accession no. P43629-1 | PENDE ET AL., FRONT. IMMUNOL | "NCBI Gene", Database accession no. 3811 | "NCBI", Database accession no. NM_000878.5. | "Uniprot", Database accession no. Q9NZQ7-3 | KLAGSBRUND'AMORE, ANNU. REV. PHYSIOL., vol. 5th, 1991, pages 217 - 39 | "International Nonproprietary Names for Pharmaceutical Substances", WHO DRUG INFORMATION, vol. 28, no. 4, 16 January 2015 (2015-01-16), pages 485 | CAS , no. 114977-28-5 | TONINI ET AL., ONCOGENE, vol. 22, 2003, pages 6549 - 6556 | FERRARAALITALO, NATURE MEDICINE, vol. 5, no. 12, 1999, pages 1359 - 1364 | SATO, INT. J. CLIN. ONCOL., vol. 8, 2003, pages 200 - 206 | PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 - 4599 | POPKOV ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 288, 2004, pages 149 - 164 | HODGINS ET AL., J. CLIN. INVEST., vol. 129, no. 9, 2019, pages 3499 - 3510 | REUSCH ET AL., MABS, vol. 6, no. 3, 2014, pages 727 - 738 | TREDER ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 34, no. 15, 2016 | ELLWANGER ET AL., J IMMUNOTHER CANCER, vol. 3, no. 2, 2015, pages 219 | AU ET AL., SCIENCE ADVANCES, vol. 6, no. 27, 2020, pages eaba8564 | ABBAS ET AL.: "Cellular and Mol. Immunology,", vol. 4th, 2000, W.B. SAUNDERS, CO. | KABAT ET AL.: "Sequences of Proteins of Immunological Interest", vol. 5th, 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH | CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 | MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745 | CICHOCKI ET AL., SCI. TRANS. MED., vol. 12, no. 568, 2020, pages eaaz5618 | ZHU ET AL., BLOOD, vol. 135, no. 6, 2020, pages 399 - 410 | ANDRADE ET AL., CANCER IMMUNOL. RES., vol. 8, 2020, pages 769 - 80 | LIU ET AL., NEW ENGL. J. MED., vol. 382, 2020, pages 545 - 53 | HARTMANN ET AL., MBO MOLECULAR MEDICINE, vol. 9, no. 9, 2017 | "Remington's Pharmaceutical Sciences", vol. 16th, 1980 | PENDE ET AL., FRONT. IMMUNOL.,, vol. 10, no. 1179, 2019 | KIM ET AL., PNAS, vol. 105, no. 8, 2008, pages 3053 - 3058 | JAMILKHAKOO, J BIOMED BIOTECHNOL, no. 298348, 2011 | KAWAGUCHI ET AL., HUM MUTAT., vol. 38, no. 7, 2017, pages 788 - 797 | ROBINSON ET AL., NUCLEIC ACIDS RESEARCH, vol. 43, 2015, pages 423 - 431 | ROE ET AL., FRONT. IMMUNOL., vol. 11, 2020, pages 583013 | CHOWELL ET AL., SCIENCE, vol. 359, no. 6375, 2018, pages 582 - 587 | CURSONS ET AL., CANCER IMMUNOLOGY RESEARCH, vol. 7, no. 7, 2019, pages 1162 - 1174 | WANG ET AL., THORAC CANCER, vol. 11, 2020, pages 191 - 197 | NAIDOO ET AL., J CLIN ONCOL, vol. 35, 2016, pages 709 - 717 | KAWAGUCHI ET AL., HUM MUTAT, vol. 38, 2017, pages 788 - 797 | ZHENG ET AL., PHARMACOGENOMICS, vol. 14, 2014, pages 192 - 200 | TIAN ET AL., NAT COMMUN, vol. 8, 2017, pages 599 | FINGERLIN ET AL., BMC GENET.,, vol. 17, 2016, pages 74 | VOORTER ET AL., HUM IMMUNOL, vol. 66, 2005, pages 826 - 835 | FURUKAWA ET AL., PLOS ONE, vol. 7, 2012, pages e33133 |